Cargando…

POSC254 The Impact of COVID-19 on European HTA Decisions

Detalles Bibliográficos
Autores principales:	Watson, C, Petrie, JL, Toomey, JA, Shaw, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8769571/ http://dx.doi.org/10.1016/j.jval.2021.11.892

Ejemplares similares

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

POSC198 Impact of COVID-19 on Influenza Vaccine Coverage Rate During the 2020/2021 Season
por: Ngami, A, et al.
Publicado: (2022)

POSC117 A Public Health and Budget Impact Analysis (BIA) of COVID-19 Vaccination in Austria
por: Traunfellner, M, et al.
Publicado: (2022)

POSC402 Impact of COVID-19 on Influenza Vaccine Sales in France, United Kingdom and United States
por: Ngami, A, et al.
Publicado: (2022)

POSC407 Monitoring of Reported COVID-19 Vaccination Rates in Community Oncology Settings
por: Harrell, R, et al.
Publicado: (2022)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

POSC102 High-Flow Nasal Cannula in Patients with COVID-19: Is a Cost-Effective Alternative?
por: Alves Junior, JM, et al.
Publicado: (2022)

POSC172 The Long-Term Acceptability of COVID-19 Hygiene Measures, for the UK General Population
por: Roberts, G, et al.
Publicado: (2022)

POSC41 Cost-Effectiveness Analysis of Remdesivir for the Treatment of COVID-19 Hospitalized Adults in Mexico
por: Ponce-de-León, A, et al.
Publicado: (2022)

POSC218 Study of Antibiotic Consumption Trends in Public Pharmacies during the COVID-19 Pandemic in Ukraine
por: Zaliska, O, et al.
Publicado: (2022)

POSC15 Addressing Glucocorticoid-Induced Hyperglycemia in COVID -19 Patients: The Expanding Role of Steroid Stewardship
por: Kochuparambil, J, et al.
Publicado: (2022)

POSC74 Considerations for Mental Health Effects in Health Economic Analyses
por: Dolph, M, et al.
Publicado: (2022)

HTA Implementation Roadmap in Central and Eastern European Countries
por: Kaló, Zoltán, et al.
Publicado: (2016)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

POSC1 The Influence of Diabetic History in the Prognosis of Hospitalized COVID-19 Patients: A Prospective Observational Study
por: Issac, A, et al.
Publicado: (2022)

POSC17 A TARGETED LITERATURE REVIEW TO COMPARE COVID-19 SYMPTOM DIARIES AND PATIENT-REPORTED CONCEPT
por: Jarodia, K., et al.
Publicado: (2022)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level
por: Calabrò, G. E., et al.
Publicado: (2018)

HTA assessment of COVID-19 interventions in Ireland
Publicado: (2020)

POSC243 Systemic Challenges in Tele-Health and Structural Solutions to Enhance Access
por: Johnson, P.A., et al.
Publicado: (2022)

HTA56 COVID-19 from the Perspective of Intellectual Property
por: Pereira da Veiga, CR, et al.
Publicado: (2022)

254 Patient perception of the impact of elexacaftor/tezacaftor/ivacaftor and the COVID-19 pandemic on physical and mental health
por: Sakon, C., et al.
Publicado: (2022)

POSC324 Clinical Pharmacist Intervention to Improve the Administration of Injectable Antiviral Agents By Nurses in the Treatment of COVID-19 Infection.
por: Nidha, A, et al.
Publicado: (2022)

POSC413 A Systematic Review of Real-World Clinical Practice Data in COVID-19: Non-Interventional Studies
por: Mishinova, S, et al.
Publicado: (2022)

The development of HTA collaboration at European level and the challenge of the EU regulation
por: Ruether, A, et al.
Publicado: (2022)

POSC185 Healthcare Utilisation, Health Inequality and the Impact of COVID-19 on Idiopathic Pulmonary Fibrosis (IPF) Care in England: A Retrospective Cohort Study
por: Bevan, J
Publicado: (2022)

Different interpretation of additional evidence for HTA by the commissioned HTA body and the commissioning decision maker in Germany: whenever IQWiG and Federal Joint Committee disagree
por: Dintsios, C. M., et al.
Publicado: (2019)

POSC374 Association of COVID-19 on Adherence to Oral Specialty Pharmacy Oncology Medications and Quality of Life of Multiple Myeloma Patients
por: Burruss, R, et al.
Publicado: (2022)

POSC419 Examining the Rate of COVID-19 Breakthrough Infections in Individuals Who Received mRNA Vaccine in the United States
por: Madge, V, et al.
Publicado: (2022)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

254 COVID-19 related outcomes in psoriasis and psoriasis arthritis patients
por: Raiker, R., et al.
Publicado: (2021)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

Alimentation Impact of Treatments of 254 Oropharyngeal Cancers (1998–2003)
por: Buiret, Guillaume, et al.
Publicado: (2011)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

POSC65 Cost-Benefit Analysis of Ready-to-Administer Noradrenaline for Hypotensive Emergency on Intensive Care
por: Griffin, E, et al.
Publicado: (2022)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

HTA257 MOVe-OUT: A Trial of Two Halves – The Impact of Heterogeneity on Cost-Effectiveness Outcomes for COVID-19
por: McConnell, D, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_trnqrh5i3elhep27u5onfg39pr